Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Pain and Blood Loss in Cesarean Section
NCT01572805Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2012
- Primary completion
- Sep 2012
- Countries
- 1
- Sponsor
- Qazvin University of Medical Sciences
- Modality
- Small Molecules
- Drugs
- melatonin
- Conditions
- postoperative painpostpartum hemorrhage (PPH)
01
Overview
Phase 2, randomised, double-blind trial of melatonin in postoperative pain and postpartum hemorrhage (PPH) (3 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Time to first requirement of analgesic supplement at 24 hours and Amount of blood loss after cesarean delivery. Started Feb 2012; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Melatonin 3mg
Melatonin 3mg sublingual
Melatonin 6mg
Melatonin 6mg sublingual
Placebo
Placebo sublingual
03
Who it enrols
Pregnant women at term (37-40 weeks) scheduled for elective or emergency lower segment cesarean section. Excludes women with risk factors for postpartum hemorrhage (multiple gestation, antepartum hemorrhage, polyhydramnios, >=2 previous C-sections, uterine rupture history), significant heart/liver/renal disease, anemia (Hb < 8 g%), or coagulopathy.
04
Endpoints
Primary
Time to first requirement of analgesic supplement
Amount of blood loss after cesarean delivery
Secondary
Hemodynamic variables
Beyond the preview
Go deeper on NCT01572805.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572805.